NervGen Pharma

Please note: The information displayed on this page might be outdated.
NervGen Pharma: NervGen Pharma is a developing novel therapeutics for patients suffering from medical conditions related to nerve damage sustained as a result of (i) injury, such as in spinal cord injury, or (ii) neurodegenerative disease, such as MS or Alzheimer's disease.

NervGen's core technology has the potential to be a disruptive technology the will change how nerve damage is perceived and treated. Our lead product targets a novel receptor, PTPσ, a neural receptor that impedes nerve regeneration, remyelination and plasticity. Inhibition of the PTPσ receptor has been shown to promote functional recovery in animal models for various indications, including spinal cord injury, MS, peripheral nerve injury, stroke and cardiac ischemia (by restoring the pacemaking function).

NervGen's lead product is NVG-291. NervGen intends to enter phase 1 clinical trials with NVG-291 in Q4 2020, and to commence phase 2 studies in 2021. Our lead indications are MS and Spinal Cord Injury
Based in...
North America
Public, USA
Market Cap
Three Bentall Centre
Suite 1703, 595 Burrard Street
Vancouver, BC V7X 1J1

Company Participants at Solebury Trout Corporate Access Calls - May 11&12

  • Bill Adams
  • Deepah Singh, Controller
  • Paul Brennan, CEO
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.